Whole brain radiotherapy and simultaneous integrated boost: is it still a viable treatment for multiple brain metastases in the era of SRS?
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, cilt.31, sa.1, ss.25-33, 2026 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.5603/rpor.108615
- Dergi Adı: REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, Directory of Open Access Journals
- Sayfa Sayıları: ss.25-33
- İstanbul Üniversitesi Adresli: Evet
Özet
Background: The objective of this study was to determine the outcomes of whole brain radiotherapy (WBRT) + simultaneous integrated boost (SIB) treatment in patients with multiple brain metastases. Materials and methods: 34 patients who were treated for multiple brain metastases with WBRT + SIB in two radiation oncology departments between 2014 and 2020 were evaluated retrospectively. Intracranial control and overall survival after radiotherapy (RT) were calculated with the Kaplan-Meier test. The prognostic factors of survival after RT were determined with Cox regression analysis. Results: The median age was 62 [interquartile range (IQR): 57-69] years. Median survival after cranial RT was 10 [95% confidence interval (CI): 7-13] months. One-year intracranial control probability after RT was 83%. Acute and late RT toxicity were observed in 2 patients. After 3 months of follow-up, 23 (68%) patients had complete/near complete response, 9 (26%) had partial response, and 2 (6%) had stable disease. In univariate analysis, the factors affecting survival after cranial RT were the presence of neurological symptoms (p = 0.003) and Karnofsky performance score (KPS, p = 0.001). The median survival of patients with and without neurological symptoms was 5 (95%CI: 4-6) months and 16 (95% CI: 5-27) months. Median survival of patients with KPS 60, 70, 80, and 90 were 1, 5, 10 and 13 months, respectively. In multivariate analysis, the only statistically significant prognostic factor was KPS [hazard ratio (HR): 0.94 95% CI: (0.89-0.99), p = 0.031]. Conclusions: WBRT+ SIB is a well-tolerated technique with a promising 1-year intracranial control rate of 83% for patients with multiple brain metastases who were not amenable to surgery and/or SRS, particularly in good performance status (KPS > 70) and without neurologic impairments.